Faculty and Disclosures

Scott A. Dulchavsky, MD, PhD, FACS - No disclosures
William R. Fry, MD, FACS - No disclosuress
Lawrence Marshall Gillman, MD - No disclosures
Mark A. Gittleman, MD, FACS - No disclosures
Jay Kenneth Harness, MD, FACS - No disclosures
Andrew W. Kirkpatrick, MD, FACS - No disclosures
Junji Machi, MD, FACS - No disclosures
Amy Catherine Sisley, MD, FACS - No disclosures
R. Stephen Smith, MD, FACS - No disclosures
Robert Alan Sofferman, MD, FACS - No disclosures
Pat Winston Whitworth, MD, FACS - No disclosures
Eugene Zierler, MD, FACS - No disclosures

Disclosure Policy

In accordance with the ACCME’s Accreditation Criteria, the American College of Surgeons must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest. Therefore, it is mandatory that both the program planning committee and speakers complete disclosure forms. Members of the program committee were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations. The ACCME defines a ‘commercial interest’ as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.” It does not consider providers of clinical service directly to patients to be commercial interests. The ACCME considers “relevant” financial relationships as financial transactions (in any amount) that may create a conflict of interest and occur within the 12 months preceding the time that the individual is being asked to assume a role controlling content of the educational activity.

The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias during the presentation. The planning committee members and speakers were contacted and the conflicts listed below have been managed to our satisfaction. However, if you perceive a bias, please advise us of the circumstances on the evaluation form.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage.

The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.